11 search results for: heterogeneity
Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity
Learn about the disease burden and heterogeneity of chronic obstructive pulmonary disease (COPD).
ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes
Drs Nicola Hanania and Francesca Polverino explore the Many Faces of COPD: From Phenotypes to Endotypes.
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management
Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.
Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes
This infographic outlines how endotyping, phenotyping, and genotyping are interrelated concepts that are crucial for improving the way patients with COPD are characterized and how understanding these concepts can better optimize patient care
ERS 2024 | Understanding the Complex Pathophysiology of COPD
Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.
ERS 2024 | What Do We Know About IL-33 Genetics?
Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.
ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling
Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
ERS 2024 | IL-33 A Promising Target
Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
